WO2014106800A8 - Substituted 2-amino pyrimidine derivatives as kinase inhibitors - Google Patents

Substituted 2-amino pyrimidine derivatives as kinase inhibitors Download PDF

Info

Publication number
WO2014106800A8
WO2014106800A8 PCT/IB2013/061358 IB2013061358W WO2014106800A8 WO 2014106800 A8 WO2014106800 A8 WO 2014106800A8 IB 2013061358 W IB2013061358 W IB 2013061358W WO 2014106800 A8 WO2014106800 A8 WO 2014106800A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidine derivatives
present
kinase
inhibitor compounds
substituted
Prior art date
Application number
PCT/IB2013/061358
Other languages
French (fr)
Other versions
WO2014106800A3 (en
WO2014106800A2 (en
Inventor
Anima BORUAH
Subramanya Hosahalli
Sunil Kumar Panigrahi
Original Assignee
Aurigene Discovery Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited
Publication of WO2014106800A2 publication Critical patent/WO2014106800A2/en
Publication of WO2014106800A3 publication Critical patent/WO2014106800A3/en
Publication of WO2014106800A8 publication Critical patent/WO2014106800A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present invention provides novel substituted 2-amino pyrimidine derivatives as kinase enzyme inhibitor compounds of formula (1), which may be therapeutically useful as kinase inhibitor, more particularly PI3K inhibitors. Formula (1) in which A, R1, R2 R3. R4, Q and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly PI3K enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
PCT/IB2013/061358 2013-01-04 2013-12-27 Substituted 2-amino pyrimidine derivatives as kinase inhibitors WO2014106800A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN39/CHE/2013 2013-01-04
IN39CH2013 2013-01-04
IN3029/CHE/2013 2013-07-05
IN3029CH2013 2013-07-05

Publications (3)

Publication Number Publication Date
WO2014106800A2 WO2014106800A2 (en) 2014-07-10
WO2014106800A3 WO2014106800A3 (en) 2014-12-18
WO2014106800A8 true WO2014106800A8 (en) 2015-02-19

Family

ID=51062519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/061358 WO2014106800A2 (en) 2013-01-04 2013-12-27 Substituted 2-amino pyrimidine derivatives as kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2014106800A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016003456A (en) 2013-09-22 2017-05-25 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use.
UA115296C2 (en) 2014-07-04 2017-10-10 Люпін Лімітед Quinolizinone derivatives as pi3k inhibitors
CN106146411A (en) * 2015-04-16 2016-11-23 上海医药工业研究院 (S) preparation method of-2-(1-amino-propyl)-5-fluoro-3-phenyl-3H-quinazoline-4-one
CN104774183B (en) * 2015-04-24 2017-10-13 合肥新诺华生物科技有限公司 A kind of auspicious relax of formoxyl cuts down the preparation method of spit of fland calcium intermediate
US10385019B2 (en) * 2015-06-30 2019-08-20 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
BR112018013955B1 (en) 2016-01-15 2024-01-16 Pfizer Inc DOPAMINE D3 BINDING COMPOUNDS OF 6,7,8,9-TETRAHYDRO-5H-PYRIDE [2,3- D] AZEPINE, PHARMACEUTICAL COMPOSITION COMPRISING THEM AND USE THEREOF
CN106588885B (en) * 2016-11-10 2019-03-19 浙江大学 2- replaces aromatic ring-pyridine derivatives and preparation and application
JP6545747B2 (en) * 2017-05-09 2019-07-17 山田化学工業株式会社 Dye compound
CN107188856A (en) * 2017-06-30 2017-09-22 宁夏医科大学 The synthetic method of the methylpyrimidine of 2 amino, 4 hydroxyl 6
AU2018388404B2 (en) 2017-12-22 2023-11-02 HiberCell Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN115010640A (en) * 2022-07-13 2022-09-06 苏州诚和医药化学有限公司 Preparation process of brivaracetam

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009081105A2 (en) * 2007-12-21 2009-07-02 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
BR112012019635A2 (en) * 2010-02-22 2016-05-03 Hoffmann La Roche pyrido [3,2-d] pyrimidine pi3k delta inhibitor compounds and methods of use

Also Published As

Publication number Publication date
WO2014106800A3 (en) 2014-12-18
WO2014106800A2 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX2013012776A (en) Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors.
PH12018501920A1 (en) Bromodomain inhibitors
WO2014128669A3 (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EA033689B9 (en) Inhibitors of kras g12c
GEP20166484B (en) Protein kinase inhibitors
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
MX2019010096A (en) 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors.
WO2016109217A3 (en) Btk inhibitors
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
SA519401322B1 (en) Heteroaryl carboxamide compounds as inhibitors of receptor-interacting serine/threonine protein kinase 2
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
SA519410865B1 (en) Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof
EA201692557A1 (en) CINOLYSINUM DERIVATIVES AS PI3K INHIBITORS
WO2014072930A3 (en) Fused pyridine derivatives as antibacterial agents
MX2015012153A (en) Pyrrolopyrimindine cdk9 kinase inhibitors.
WO2016165205A8 (en) Novel bcr-abl kinase inhibitor
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MY187891A (en) Tetrahydropyridine derivatives as fabi inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 13870204

Country of ref document: EP

Kind code of ref document: A2